Figure 2: Overall survival of patients with locally advanced rectal cancer receiving capecitabine/irinotecan +/− cetuximab based chemoradiotherapy as preoperative treatment (). Shown are survival curves of patients treated with CapIri (solid curve; ) versus patients with KRAS WT receiving CapIri + cetuximab (dotted curve; ), .